Cardiff Oncology
Cardiff Oncology's revenue fell 13.2% to $1 million in fiscal 2025. Its operating margin was −8,256.3%, down from −7,123.1% a year earlier. Free cash flow was −$38 million. The diluted share count rose 40.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cardiff Oncology does
Cardiff Oncology is a clinical-stage biotech company, which means it is still testing its medicine in people and has none approved for sale. Its only drug candidate is onvansertib, a pill that blocks PLK1, a protein cancer cells need to divide. The company tests it alongside standard cancer treatments.
Its main study is a mid-stage (Phase 2) trial in people newly treated for colorectal cancer that has spread and carries a RAS gene mutation. The trial enrolled 110 patients and is run with Pfizer Ignite, a Pfizer service for biotech companies. If the results support it, Cardiff plans a late-stage (Phase 3) trial aimed at approval by the FDA. Doctors are also running their own trials of the drug in pancreatic, small cell lung and triple negative breast cancer, and in a blood cancer called CMML.
Cardiff does not sell any products. It licenses the patents behind onvansertib from Nerviano Medical Sciences, which in February 2026 said Cardiff was in material breach of their license. The company had 31 employees in February 2026, and has said there is substantial doubt it can keep operating without raising more money.
Its biggest risks, as it describes them
- It will need to raise a lot more money and may not be able to keep going, as it has warned.
- Onvansertib, its only drug candidate, may fail in trials, cause harmful side effects or never win approval.
- Nerviano could end the license behind onvansertib over the breach it alleges.
- Its reliance on outside companies to make the drug and run its trials.
- It has never earned a profit and may never do so.
Income statement
Cardiff Oncology lost money in fiscal 2025: a net loss of $46 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 141 | 105 | 75 | 92 | 58 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −141 | −105 | −75 | −92 | −58 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 22.3x | 14.2x | 7.4x | 7.1x | 3.7x |
| Quick ratio | 22.3x | 14.2x | 7.4x | 7.1x | 3.7x |
Cash flow
Projections
Project Cardiff Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.1 million of Cardiff Oncology shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | Gary W PaceDirector | Bought | 687,285 | $1.46 | $1.0 million | Form 4 |
| Jul 14, 2026 | Mani MohindruChief Executive Officer, Director | Bought | 34,364 | $1.46 | $50,171 | Form 4 |
| Jun 18, 2026 | Gary W PaceDirector | Bought | 30,000 | $1.22 | $36,600 | Form 4 |
| Jun 18, 2026 | Mani MohindruChief Executive Officer, Director | Bought | 24,703 | $1.21 | $29,891 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 2 of 8 |
| Rule of 40 | −6,422.1% | −5,490.5% | −6,415.7% |
| Altman Z'' | −5.76 | −4.62 | −20.45 |
| Accruals ratio | −10.7% | −8.7% | −10.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 2 of 8 | 2 of 8 | 2 of 8 |
Compare
Put Cardiff Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology | FY25 | −13.2% | −8,256.3% | −6,402.5% | — | — | 2 | |
| PMGC Holdings | FY25 | — | — | −1,080.5% | — | — | — | Compare |
| Silence Therapeutics | FY25 | −98.7% | −16,292.8% | −11,149.5% | — | — | — | Compare |
| ImageneBio | FY25 | −77.1% | −6,056.4% | — | — | — | — | Compare |
| BioRestorative Therapies | FY25 | −10.3% | −4,350.1% | −3,031.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Revenue growth | 21.8% | 32.6% | −25.1% | −35.3% | 49.6% | −1.9% | 7.5% | 26.4% | 40.0% | −13.2% |
| Gross profit | −1 | −1 | −0 | 0 | — | — | — | — | — | — |
| Research and development | 15 | 8 | 8 | 11 | 11 | 17 | 27 | 33 | 37 | 35 |
| Operating income | −40 | −26 | −17 | −17 | −19 | −29 | −40 | −45 | −49 | −49 |
| Net income | −39 | −25 | −16 | −16 | −19 | −28 | −39 | −41 | −45 | −46 |
| Diluted EPS (US$) | −1.37 | −51.76 | −8.26 | −2.80 | −1.08 | −0.73 | −0.89 | −0.93 | −0.95 | −0.69 |
| Diluted shares (millions) | 30 | 0 | 2 | 6 | 21 | 39 | 44 | 45 | 48 | 67 |
| Cash flow | ||||||||||
| Cash from operations | −31 | −23 | −13 | −13 | −16 | −23 | −34 | −31 | −38 | −38 |
| Capital expenditure | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow | −32 | −23 | −13 | −13 | −17 | −23 | −35 | −31 | −38 | −38 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 4 | 2 | 1 | 2 | 3 | 4 | 4 | 5 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 38 | 8 | 12 | 10 | 131 | 141 | 105 | 75 | 92 | 58 |
| Debt incl. finance leases | 16 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 44 | 12 | 14 | 13 | 135 | 150 | 116 | 82 | 97 | 62 |
| Total liabilities | 24 | 6 | 4 | 6 | 7 | 9 | 10 | 12 | 14 | 16 |
| Shareholders' equity | 20 | 6 | 10 | 7 | 128 | 140 | 106 | 70 | 83 | 45 |
| Margins and ratios | ||||||||||
| Gross margin | −354.1% | −258.4% | −57.9% | 100.0% | — | — | — | — | — | — |
| Operating margin | −10,534.9% | −5,064.4% | −4,507.6% | −6,817.8% | −5,214.9% | −8,037.6% | −10,337.3% | −9,305.7% | −7,123.1% | −8,256.3% |
| Net margin | −10,287.8% | −4,928.1% | −4,351.1% | −6,709.7% | −5,275.2% | −7,880.5% | −10,026.9% | −8,492.0% | −6,651.7% | −7,732.0% |
| Free cash flow margin | −8,361.5% | −4,626.4% | −3,490.2% | −5,451.1% | −4,515.4% | −6,474.9% | −9,022.3% | −6,448.6% | −5,530.4% | −6,402.5% |
| Rule of 40 (growth + FCF margin) | −8,339.7% | −4,593.8% | −3,515.3% | −5,486.4% | −4,465.8% | −6,476.8% | −9,014.8% | −6,422.1% | −5,490.5% | −6,415.7% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −114.5% | −189.6% | −198.4% | −188.7% | −28.5% | −21.1% | −31.4% | −47.1% | −59.5% | −71.5% |
| Return on assets | −68.0% | −88.6% | −124.4% | −120.4% | −26.1% | −19.9% | −29.1% | −41.9% | −50.8% | −57.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |